

AOTI enters into strategic relationship for Chinese market

21 January 2019 | News

The multi-year agreement includes minimum sales performance expectations totaling close to \$18 million.



AOTI Inc. has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen (TWO2) therapy wound healing products into the People's Republic of China. The multi-year agreement includes minimum sales performance expectations totaling close to \$18 million.

Both companies are working closely together to achieve National Medical Products Administration (NMPA) registration and approval for the TWO2 therapy product line in China, while in parallel generating market awareness and clinical acceptance of this unique therapy across the country. Following this initial phase and after gaining marketing approval, Nanning will aggressively market the product line nationwide through both its direct sales force and network of regional distribution partners.

With growing prevalence, it is estimated that there are at least 109.6 million adults with diabetes in China already, resulting in over 16 million patients likely suffering from Diabetic Foot Ulcers (DFU) alone. China's healthcare market is growing at an unprecedented CAGR of about 12%. With healthcare spending expected to reach \$1 trillion by 2020.